sever
acut
respiratori
syndrom
coronaviru
becom
pandem
diseas
spread
global
caus
death
despit
immens
ongo
global
effort
efficaci
drug
fight
plagu
identifi
patient
admit
intens
care
unit
icu
respiratori
distress
manag
mostli
mean
support
care
base
oxygen
mainten
sever
author
report
preval
hypertens
diabet
cardiovascular
cerebrovascular
diseas
comorbid
inde
frequent
among
patient
suggest
condit
like
aggrav
complic
prognosi
aforement
diseas
common
latent
chronic
inflammatori
state
may
associ
alter
laboratori
paramet
typic
metabol
syndrom
insulin
resist
sever
patient
laboratori
marker
inflamm
creactiv
protein
ddimer
serum
ferritin
lactat
dehydrogenas
elev
mani
patient
assess
sinc
day
ill
onset
increas
seem
predict
advers
prognosi
hypothesi
drug
belong
famili
thiazolidinedion
tzd
pioglitazon
rosiglitazon
approv
treat
condit
insulin
resist
accompani
inflamm
could
amelior
prognosi
patient
diabet
hypertens
cardiovascular
disord
comorbid
tzd
agonist
act
nuclear
receptor
therebi
trigger
certain
transcript
factor
tzd
wide
use
diabet
first
decad
centuri
although
concern
rais
possibl
side
effect
associ
longterm
treatment
use
recent
revalu
antiinflammatori
properti
numer
medic
condit
sever
acut
respiratori
syndrom
coronaviru
becom
pandem
diseas
spread
global
caus
death
although
sever
treatment
trial
clinic
evalu
specif
efficaci
therapi
avail
moment
patient
admit
intens
care
unit
icu
respiratori
distress
manag
mostli
mean
support
care
base
oxygen
mainten
moreov
dramat
situat
current
face
hospit
europ
particular
hinder
accur
critic
evalu
publish
clinic
data
therapeut
respons
treatment
util
china
experi
nevertheless
although
initi
report
come
certain
limit
emerg
patient
previou
cardiovascular
metabol
diseas
could
addit
metaanalysi
aim
show
preval
comorbid
patient
report
hypertens
diabet
cardiovascular
diseas
respiratori
system
diseas
present
comorbid
may
risk
factor
sever
patient
compar
nonsever
patient
presenc
condit
suggest
frequent
incid
metabol
syndrom
condit
although
systemat
report
appear
advers
prognosi
like
associ
peng
et
al
report
among
nonsurviv
patient
bmi
kgm
addit
creactiv
protein
elev
patient
particular
creactiv
protein
elev
progress
toward
wors
condit
accumul
evid
suggest
subgroup
patient
sever
might
cytokin
storm
syndrom
thu
identif
treatment
hyperinflamm
recommend
order
reduc
mortal
regard
drug
tocilizumab
receptor
blocker
approv
patient
pneumonia
elev
china
particular
sarscov
infect
increas
plasma
basic
fgf
gmcsf
pdgf
vegf
concentr
icu
intens
care
unit
patient
sever
stage
diseas
higher
plasma
level
gcsf
nonicu
patient
suggest
hyperinflammatori
condit
also
known
cytokin
storm
addit
specif
predict
sever
adult
patient
assess
ddimer
concentr
parallel
propos
mechan
strong
inflammatori
respons
could
link
uncontrol
pulmonari
inflamm
consequ
lethal
recent
discuss
neuroinvas
potenti
respiratori
failur
patient
recent
debat
although
evid
possibl
base
mostli
studi
corona
virus
similar
sar
cov
yu
f
et
al
suggest
conceiv
rapid
respiratori
failur
observ
number
patient
could
due
spread
brain
either
olfactori
nerv
vagu
nerv
howev
hemat
lymphat
rout
also
consid
brain
viru
may
reach
brainstem
import
cardiorespiratori
function
locat
therein
affect
unpredict
consequ
hypothesi
support
studi
report
high
number
sever
affect
patient
report
neurolog
manifest
headach
impair
conscious
consider
may
worth
highlight
mani
patient
report
lose
olfactori
gustatori
sens
although
best
knowledg
problem
accur
document
well
known
number
virus
enter
brain
olfactori
rout
time
antivir
antibodi
directli
access
olfactori
neuron
see
review
addit
share
notabl
homolog
sequenc
sarscov
sinc
sarscov
report
brain
like
hyposmia
could
due
passag
brain
olfactori
rout
moreov
also
possibl
passag
brain
could
least
partial
respons
acut
respiratori
failur
patient
among
treatment
use
known
antivir
antibiot
secondari
sepsi
sometim
corticosteroid
frequent
use
drug
nevertheless
appear
condit
like
expos
patient
higher
vulner
yet
consid
therapeut
target
hand
seem
last
stage
pulmonari
damag
state
hyper
inflamm
sustain
cytokin
storm
may
overwhelm
immun
defenc
respons
lead
multipl
organ
failur
deceas
handl
elev
level
test
carri
use
tocilizumab
monoclon
antibodi
target
seem
improv
prognosi
infect
patient
sever
respiratori
distress
hand
efficaci
glucocorticoid
antiinflammatori
drug
often
use
often
handl
condit
patient
question
moreov
seem
indic
assess
condit
overweight
metabol
syndrom
insulin
resist
guid
select
suitabl
treatment
patient
light
hypothesi
drug
pioglitazon
could
potenti
use
reduc
inflamm
consequ
risk
death
associ
least
patient
manifest
condit
metabol
syndrom
pioglitazon
belong
famili
thiazolidinedion
tzd
ie
drug
commonli
use
treat
insulin
resist
know
follow
fact
insulin
resist
amplifi
inflamm
associ
sever
cardiovascular
risk
factor
associ
increas
creactiv
protein
produc
procoagul
state
increas
fibrinogen
plasminogen
activ
inhibitor
rais
mani
concern
regard
abil
patient
diabet
respond
properli
infect
reason
consid
also
inflammatori
laboratori
marker
elev
great
interest
pioglitazon
produc
antiinflammatori
effect
assay
high
sensit
creactiv
protein
within
short
term
interv
start
therapi
specif
pioglitazon
mgday
three
month
significantli
reduc
insulin
resist
individu
without
manifest
hyperglycaemia
match
age
gender
adipos
four
month
mgday
treatment
pioglitazon
reduc
monocyt
gene
protein
express
lymphocyt
also
report
pioglitazon
inhibit
secret
proinflammatori
cytokin
eg
increas
antiinflammatori
one
eg
astrocyt
stimul
lipopolysaccharid
also
shown
potenti
decreas
ferritin
rat
model
angiotensin
ii
induc
hypertens
final
wonder
whether
pioglitazon
direct
action
lung
inflamm
fibrosi
found
pioglitazon
attenu
lung
injuri
modul
adipos
inflamm
cecal
ligat
punctur
clp
model
mice
studi
pioglitazon
day
significantli
reduc
mrna
express
periton
lavag
fluid
clp
group
addit
report
pioglitazon
may
exert
direct
effect
lung
inflamm
fibrosi
reduc
lung
fibrot
reaction
silica
rat
normal
character
overproduct
tnfa
hypothesi
either
consequ
inflamm
respons
spread
brain
concern
believ
compel
evid
tzd
display
central
antiinflammatori
properti
neurolog
disord
report
therapeut
use
psychiatr
neurolog
condit
depress
alzheim
diseas
anim
model
parkinson
although
parkinson
patient
pioglitazon
significantli
alter
level
inflammatori
biomark
week
treatment
mgday
interestingli
pioglitazon
rosiglitazon
treatment
attenu
elev
inflammatori
marker
decreas
glutam
transport
express
primari
mix
cultur
astrocyt
microglia
caus
exposit
viral
protein
iehiv
ada
similarli
result
replic
vivo
treatment
regard
use
tzd
emerg
concern
inevit
rais
drug
efficaci
patient
reaction
time
short
term
administr
patel
et
al
show
pioglitazon
abl
suppress
neuroinflamm
maintain
mitochondri
respir
administ
acut
model
spinal
cord
injuri
mice
addit
subchron
treatment
pioglitazon
exert
anticonvuls
effect
pentylentetrazoleinduc
seizur
mice
probabl
induct
constitut
nitric
oxid
synthas
pioglitazon
show
shortterm
week
trial
antiinflammatori
effect
lower
creactiv
protein
men
advanc
nephropathi
pioglitazon
administ
acut
effect
abrog
dysfunct
attenu
neutrophilia
oxid
stress
lpsinduc
model
acut
lung
inflamm
guinea
pig
base
report
confid
pioglitazon
could
efficaci
acut
subchron
treatment
premis
suggest
treatment
pioglitazon
agonist
rational
treatment
look
clinic
profil
covid
patient
one
studi
emerg
progress
group
elev
creactiv
protein
decreas
albumin
level
second
studi
show
patient
hospit
among
laboratori
marker
ddimer
serum
ferritin
lactat
dehydrogenas
ddimer
highsensit
cardiac
troponin
significantli
elev
patient
lymphocyt
count
significantli
decreas
variou
time
point
ill
onset
day
hospit
third
studi
show
admiss
patient
lymphocytopenia
patient
elev
level
creactiv
protein
sever
diseas
promin
laboratori
abnorm
given
pioglitazon
abl
reduc
mani
inflammatori
paramet
consid
comorbid
diabet
hypertens
cardiovascular
disord
indic
gener
inflamm
associ
metabol
syndrom
lipid
profil
alter
condit
improv
pioglitazon
therefor
suggest
clinic
trial
drug
tzd
consid
support
therapi
covid
final
would
like
stress
pioglitazon
administ
patient
statin
report
addit
pioglitazon
atorvastatin
reduc
creactiv
protein
laboratori
marker
inflamm
author
declar
conflict
interest
